Back to top

Bull of the Day

Spherix, Inc. (SPEX) announced that it was shifting focus on the company s phase III candidate from type-2 diabetes to triglyceride lowering. This may come as a surprise to some Spherix investors; however, the strategy move makes sense to us considering the bar moved significant higher for approval of new type-2 diabetes drugs following the new FDA guidelines on cardiovascular safety established in March 2008.

This was after Spherix has already designed the current phase III protocol. The new path to market for triglycerides will be cheaper and quicker for the company. In the meantime, Spherix will look to partner D-tagatose for type-2 diabetes with a larger pharmaceutical organization. This partnership becomes more likely after the phase III NEET data is released later this summer.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%